The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report

Abstract

The coronavirus disease 19 (COVID-19) is responsible for the current worldwide pandemic. Treatment and prophylaxis are still under investigation. Convalescent plasma therapy could be an alternative. We report a case of a 41-year-old patient, at 28 weeks of gestation, was hospitalized with COVID-19. On the 10 th day after onset of symptoms, the clinical picture worsened, and she required high-flow oxygen therapy (30L/minute), with 92% oxygen saturation, and chest X-ray showing mild bilateral opacities at lung bases. Blood tests showed D-dimer 1,004ng/ mL, C-reactive protein 81mg/L, pro-calcitonin 0.05ng/mL and interleukine-6 42.9pg/mL. The therapy chosen was Tazocin ® 12g/day, vancomycin 2g/day, and methylprednisolone 40mg/day. In addition, convalescent plasma therapy was administered (275mL) uneventfully, including SARS-CoV-2 antibodies and neutralizing antibodies >1:160. The patient had a fast recovery. The early administration of convalescent plasma, with high titers of neutralizing antibodies, may be an alternative option for severe COVID-19 during pregnancy, until further studies demonstrate an efficient and safe treatment or prophylaxis.

Convalescent plasma use in pregnant patients with COVID19 related ARDS: a case report and literature review

“…All the cases about pregnant women suffering from severe ARDS due to SARS-CoV-2 infection and treated with CP show maternal survival. In most of cases preterm cesarean sections has been needed [12][13][14] but in many cases normal ongoing of the pregnancy has been registered [15][16][17]. Just few cases showed intrauterine neonatal death as a consequence of the complicated maternal clinical picture [18,19].…”